Almac Group Joins Science Based Targets Initiative
Union adds to company’s goal of reaching net zero emissions by 2045.
Almac Group, a contract development and manufacturing organization (CDMO), announced it has officially joined the Science Based Targets Initiative (SBTi), which advocates for the best practices in science-based target settings. The company credits this move as the latest step taken with the objective of reaching net zero emissions by 2045.
The collaboration, which is headed by CDP, the United Nations Global Compact, the World Resources Institute (WRI), and the Worldwide Fund for Nature (WWF), is one of multiple steps Almac Group has taken to reach net zero. Other efforts include the expansion of accreditations with the International Standard Organization (ISO), accepted as the gold standard in health, safety, and environmental activity.
“Developing science-based targets for the reduction of greenhouse gas emissions is a crucial next step and demonstrates the commitment to our environmental responsibilities at Almac,” said Niall Harkin, executive director, Almac Group. “At Almac, we see transparency and alignment to internationally recognized standards as essential in demonstrating our commitment to making a measurable and positive impact on our planet.Signing up to SBTi, coupled with our latest ISO certifications represent an essential part of Almac’s plan to reach net-zero by 2045 and we are proud to mark these milestones in our progress.”
Reference: Almac Group signs up to Science Based Targets initiative. (2023, July 4).
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
The Rise of Predictive Engagement Tools in Clinical Trials
November 22nd 2024Patient attrition can be a significant barrier to the success of a randomized controlled trial (RCT). Today, with the help of AI-powered predictive engagement tools, clinical study managers are finding ways to proactively reduce attrition rates in RCTs, and increase the effectiveness of their trial. In this guide, we look at the role AI-powered patient engagement tools play in clinical research, from the problems they’re being used to solve to the areas and indications in which they’re being deployed.
